New Zealand markets close in 6 hours 16 minutes

Seres Therapeutics, Inc. (MCRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.22-0.10 (-1.58%)
At close: 4:00PM EDT
6.20 -0.02 (-0.32%)
After hours: 05:19PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5571.41M
Enterprise value 3401.69M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)18.62
Price/book (mrq)5.65
Enterprise value/revenue 313.41
Enterprise value/EBITDA 7-3.25

Trading information

Stock price history

Beta (5Y monthly) 3.85
52-week change 3-79.08%
S&P500 52-week change 334.68%
52-week high 338.50
52-week low 35.41
50-day moving average 36.56
200-day moving average 314.12

Share statistics

Avg vol (3-month) 31.78M
Avg vol (10-day) 31.05M
Shares outstanding 591.72M
Implied shares outstanding 6N/A
Float 863.61M
% held by insiders 19.05%
% held by institutions 192.84%
Shares short (29 Sep 2021) 49.1M
Short ratio (29 Sep 2021) 43.8
Short % of float (29 Sep 2021) 417.54%
Short % of shares outstanding (29 Sep 2021) 49.92%
Shares short (prior month 30 Aug 2021) 46.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-438.42%

Management effectiveness

Return on assets (ttm)-44.34%
Return on equity (ttm)-745.69%

Income statement

Revenue (ttm)29.96M
Revenue per share (ttm)0.34
Quarterly revenue growth (yoy)-12.90%
Gross profit (ttm)-57.35M
EBITDA -125.37M
Net income avi to common (ttm)-132.33M
Diluted EPS (ttm)-1.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)214.55M
Total cash per share (mrq)2.34
Total debt (mrq)44.84M
Total debt/equity (mrq)44.36
Current ratio (mrq)4.00
Book value per share (mrq)1.10

Cash flow statement

Operating cash flow (ttm)-112.98M
Levered free cash flow (ttm)-64.52M